Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants.
Journal
Current opinion in critical care
ISSN: 1531-7072
Titre abrégé: Curr Opin Crit Care
Pays: United States
ID NLM: 9504454
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
6
2
2020
medline:
2
12
2020
entrez:
6
2
2020
Statut:
ppublish
Résumé
This review focuses on recent relevant literature that examines the reversal of direct oral anticoagulants (DOACs) in patients with intracranial hemorrhage (ICH). The aim of this review is to provide an insightful description of available reversal agents and their clinical utility. Increases in prescribing of DOACs has led to the introduction of drug-specific reversal agents. The clinical trials that evaluated these agents did not include a comparator arm making it difficult to determine if they are clinically superior to nonspecific reversal agents. Numerous options for reversal of DOAC-associated ICH are currently available. Recent clinical trials have demonstrated drug-specific reversal agents are effective in this setting, but additional research is needed to determine whether these agents should be routinely preferred over nonspecific reversal agents.
Identifiants
pubmed: 32022724
doi: 10.1097/MCC.0000000000000706
pii: 00075198-202004000-00008
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-128Références
Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA 2018; 319:463–473.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–891.
Bristol-Myers Squibb Company. Eliquis (apixaban) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf (revised June 2019), accessed August 30, 2019.
Portola Pharmaceuticals, Inc. Bevyxxa (betrixaban) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf (revised June 2017), accessed August 30, 2019.
Boehringer Ingelheim Pharmaceuticals. Pradaxa (dabigatran) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf (revised November 2011), accessed August 30, 2019.
Daiichi Sankyo, Inc. Savaysa (edoxaban) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf (revised January 2015), accessed August 30, 2019.
Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202439s017lbl.pdf (revised August 2019), Accessed August 30, 2019.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799–808.
Bauersachs R, Berkowitz SD, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499–2510.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342–2352.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation 2019; 140:e125–e151.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071–2104.
Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2015; 11:e442–e444.
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378:615–624.
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36:2017–2023.
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2019; JCO1901461.
Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: aristophanes subgroup analysis. J Am Coll Cardiol 2019; 73: (9 Supplement 1): 435.
Choi Y, Kushnir M, Billett HH. Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI ≥40. Blood 2017; 130: (Suppl 1): 1105–11105.
Feldberg J, Patel P, Farrell A, et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant 2019; 34:265–277.
Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33:2821–2830.
Wong SL, Marshall LZ, Lawson KA. Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid. Am J Manag Care 2018; 24 ((8 Spec No)):S309–S314.
Ziakas PD, Kourbeti IS, Poulou LS, et al. Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the ‘rubber effect’. PLoS One 2018; 13:e0198674.
Veltkamp R, Horstmann S. Treatment of intracerebral hemorrhage associated with new oral anticoagulant use. Clin Lab Med 2014; 34:587–594.
Shah SB, Pahade A, Chawla R. Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): an update. Indian J Anaesth 2019; 63:169–181.
Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacother J Hum Pharmacol Drug Ther 2017; 37:236–248.
Siriez R, Evrard J, Dogné JM, et al. Betrixaban: impact on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2018; 118:1203–1214.
Stacy ZA, Call WB, Hartmann AP, et al. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther 2016; 5:1–18.
Khawar H, Kelley W, Guzman N. Fresh frozen plasma (FFP). StatPearls [Internet] 2019; Treasure Island, FL: StatPearls Publishing, Available from: http://www.ncbi.nlm.nih.gov/books/NBK513347/ [cited October 3, 2019].
Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion (Paris) 2012; 52 (s1):9S–19S.
Christos S, Naples R. Anticoagulation reversal and treatment strategies in major bleeding: update. West J Emerg Med 2016; 17:264–270.
Zhou W, Zorn M, Nawroth P, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44:771–778.
Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42:3594–3599.
Kumar R, Smith RE, Henry BL. A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage: a single-center university hospital experience. J Intensive Care Med 2015; 30:462–472.
Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013; 8:1533–1539.
Frontera JA, Lewin JJ III, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24:6–46.
Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542–547.
Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116:94–102.
Perzborn E, Gruber A, Tinel H, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110:162–172.
Herzog E, Kaspereit F, Krege W, et al. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding. Thromb Res 2015; 135:554–560.
Herzog E, Kaspereit F, Krege W, et al. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. J Thromb Haemost 2015; 13:2220–2226.
Herzog E, Kaspereit F, Krege W, et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology 2015; 122:387–398.
Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107:253–259.
Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014; 133:671–681.
Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127–2137.
Steiner T, Köhrmann M, Schellinger PD, Tsivgoulis G. Non-vitamin K oral anticoagulants associated bleeding and its antidotes. J Stroke 2018; 20:292–301.
Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8:149–154.
Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiol J Am Soc Anesthesiol 2008; 109:918–926.
Marlu R, Hodaj E, Paris A, et al. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217–224.
Majeed A, Ågren A, Holmström M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130:1706–1712.
Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in nonvitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 2018; 83:186–196.
Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131:82–90.
Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121:3554–3562.
Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med 2017; 377:431–441.
Šinigoj P, Malmström RE, Vene N, et al. Dabigatran concentration: variability and potential bleeding prediction in ‘real-life’ patients with atrial fibrillation. Basic Clin Pharmacol Toxicol 2015; 117:323–329.
Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375:1131–1141.
Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373:2413–2424.
Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326–1335.
Trial of andexanet in ICH patients receiving an oral FXa inhibitor [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03661528 [cited August 30, 2019].
Bower Matthew M, Sweidan Alexander J, Mohammad S, et al. Contemporary reversal of oral anticoagulation in intracerebral hemorrhage. Stroke 2019; 50:529–536.
Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood 2019; 133:425–435.
Kuramatsu JB, Sembill JA, Huttner HB. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. Crit Care Lond Engl 2019; 23:206.
Portola Pharmaceuticals, Inc. Andexxa (andexanet alfa) [package insert]. US Food and Drug Administration website. https://www.portola.com/wp-content/uploads/Andexxa-prescribing-information-pdf.pdf (revised December 2018), accessed August 30, 2019.
Ansell JE, Bakhru SH, Laulicht BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017; 117:238–245.
Ansell JE, Laulicht BE, Bakhru SH, et al. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res 2016; 146:113–118.
Kalathottukaren MT, Creagh AL, Abbina S, et al. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. Blood Adv 2018; 2:2104–2114.